You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
A*STAR and Tan Tock Seng Hospital developed the test, which is the first diagnostic to be deployed in the country's hospitals since the outbreak began in December.
PacBio will try to take the Sequel II to the clinic in China with the help of Berry Genomics and is open to partnerships globally, including with Illumina.
The blood test screens individual blood donations for four common species of the parasite Babesia, which can cause anemia and other potentially fatal conditions.
Centogene opened a Boston office in December and plans to open a lab there in a few months as it awaits an FDA decision on its clinical tool.
The Seoul-based company also recently raised $1.9 million in series B funding and is targeting between $7 million and $8 million to close the round.
NGeneBio said this week that its next-generation sequencing panel has been approved as an IVD, the first NGS test to be cleared in Korea.
The test runs on the GeneSTAT system, and has demonstrated 100 percent sensitivity, 99.6 percent specificity, and 100 percent reproducibility.
Gencurix's assay can be used to select which non-small cell lung cancer patients will respond to tyrosine kinase inhibitors.
Researchers have developed a robotic lab assistant, the Verge reports.
CBC News reports Canada's Supreme Court is to rule on the constitutionality of the country's genetic non-discrimination law today.
The Associated Press reports the World Health Organization is sending experts to China to investigate the animal source of SARS-CoV-2.
In Science this week: atlas of affected cell populations in idiopathic pulmonary fibrosis, and more.